CSL LIMITED与合作方达成开发协议,将致力于研发一种创新治疗方案,旨在为正在使用Fxa抑制剂的患者恢复血液凝固能力。
CSL LIMITED与合作方达成开发协议,将致力于研发一种创新治疗方案,旨在为正在使用Fxa抑制剂的患者恢复血液凝固能力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.